Professor Celia Morgan
Professor of Psychopharmacology


Research interests

My research examines both the benefits and side effects of illicit drugs and I am interested in how childhood adversity and deprivation relate to addiction and whether treatments can modulate these processes. I use a range of techniques from experience sampling and qualitative interviews to cognitive testing and functional and structural neuroimaging (DTI and VBM). We also run clinical trials of illict drugs combined with psychological therapies in the treatment of addiction at the NIHR Exeter Clinical Research Facility.

Research projects

  • Cannabidiol for nicotine dependence
  • Ketamine for reduction of relapse in alcohol use disorder
  • Cannabis in the management of withdrawal symptoms in opioid use disorder
  • Can biomedical modelling predict relapse in people on opioid substitution medication using mHealth solutions?
  • Trauma and addiction: the role of the endogenous opioid system
  • Harmful alcohol use and ruminative thinking

Exeter Translational Addiction Partnership (ETAP)
Exeter Translational Addiction Partnership seeks to bridge between research on substance dependence at University of Exeter and the therapeutic services delivered by the charity EDP Drug & Alcohol Services to the community and prison population.

Research grants:

Morgan CJA, Curran HV and Lingford-Hughes, A (2014) Medical Research Council (£1.3 million) Reducing relapse using the NMDA-receptor antagonist, ketamine. (Prinicpal Investigator)

Morgan CJA; White M; Grand A (2019-2020) Wellcome Trust (£69 000) REFLECT: Experiences of mental health in deprived coastal communities  (PI)

Morgan CJA; Lethenborg T; Hartley L (2019-2020) Medical Research Council (£89 690) Biomedical modelling to predict relapse in people with opioid use disorder using mHealth solutions (PI)

Curran HV & Morgan CJA (2012) Medical Research Council (£1.4 million) Cannabidiol as a treatment for cannabis dependence (Co-investigator)

Morgan, CJA, Stevens T, Mcandrew A (2014-2016) Medical Research Council (£134 000)  Cannabidiol and cue reactivity in smoking cessation: a neuroimaging study

Morgan, CJA  (2012) Medical Research Foundation (£28 000) Tackling the harms associated with the use of skunk cannabis (Principal Investigator)

Morgan CJA (2011) European College of Neuropsychopharmacology (€20 000) Endocannabinoid system and vulnerability to psychosis in cannabis users. (Principal Investigator)

Curran, H.V & Morgan C.J.A. (2008-2011) Medical Research Council: (£765 000): What determines and individual’s vulnerability to the harmful effects of cannabis? (Co-Investigator)

Kamboj, S. Morgan, C.J.A. Curran, H.V. (2009 -2011) Medical Research Council: (£258 000); Exploring the potential for D-Cycloserine and Cannabidiol to enhance exposure therapies for substance dependence (Co-Investigator)

Morgan, C.J.A. (2009) Beacon Bursary Fund for Public Engagement, UCL (£1500) : K-Day: A day of dialogue between ketamine users, addiction professionals and policy makers – Nominated for public engagement in science award (Principal Investigator)

Morgan C.J.A. & H.V. Curran (2008) Charitable donation from the Beckley Foundation (£10K) for developing an international survey of users’ views on the effects of psychoactive drugs (Co-investigator)

Curran, H.V. & Morgan, C.J.A. (2008-2009) Alcohol Education and Research Council Small Project Grant £4,790 The acute effects of alcohol on prospective memory and related executive functions. (Co-investigator)

Research grants

  • 2014 Medical Research Council
    Reducing Relapse with the NMDA-receptor antagonist ketamine


Back | Top of page | Edit Profile | Refresh page